207_Combined course Presentations

The traditional drug development paradigm

Phase I

Phase II

Phase III

Safety

Efficacy in selected tumors

Meaningful benefit in a randomized setting against existing standard

Tolerability

ORR

OS

Pharmacokinetics TTP Pharmacodynamics PFS Preliminary antitumor activity